Investor Presentaiton
Research framework applied to Oncology builds on our
scientific depth in immuno-oncology
Strategy:
Build a portfolio of foundational assets to address key tumor intrinsic and tumor extrinsic mechanisms,
where combinations will be critical for durable responses with transformational potential.
|| ||
We have deep expertise in tumor
extrinsic biology
Immune Checkpoints
Only company with three approved T cell
checkpoint inhibitors (CPIs)
Insights from translational datasets to
guide the next-generation of
transformational medicines
Bristol Myers Squibb™
Tumor Extrinsic
Adaptive and
Innate Immunity
Stroma
Next-gen T cell CPIs
Anti-CTLA4 next-gen, anti-TIGIT
bi-specific, dual DGKα/ inhibitor
Other immune cells
Tregs anti-CCR8
Myeloid anti-ILT4
NK cells anti-NKG2A
Aberrant Stromal Biology
Neoantigens
JNK inhibitor, TGFB inhibitor
Not for Product Promotional Use
22View entire presentation